» Articles » PMID: 32879962

A Comprehensive Systematic Review of the Effects of Naringenin, a Citrus-Derived Flavonoid, on Risk Factors for Nonalcoholic Fatty Liver Disease

Overview
Journal Adv Nutr
Publisher Elsevier
Date 2020 Sep 4
PMID 32879962
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Nonalcoholic fatty liver disease (NAFLD) has become the most common cause of liver dysfunction worldwide. Recently, some natural compounds have attracted growing interest in the treatment of NAFLD. In this context, most attention has been paid to natural products derived from fruits, vegetables, and medicinal herbs. Naringenin, a natural flavanone, has been revealed to have pharmacological effects in the treatment of obesity and associated metabolic disorders such as NAFLD. The aim of this study was to examine the therapeutic effects of naringenin and its possible mechanisms of action in the management of NAFLD and related risk factors. The current systematic review was performed according to the guidelines of the 2015 PRISMA (Preferred Reporting Items for Systematic Review and Meta-Analysis) statements. We searched PubMed/Medline, Science Direct, Scopus, ProQuest, and Google Scholar databases up until February 2020. Of 1217 full-text articles assessed, 36 studies met the inclusion criteria. The evidence reviewed in the present study indicates that naringenin modulates several biological processes related to NAFLD including energy balance, lipid and glucose metabolism, inflammation, and oxidative stress by different mechanisms. Overall, the favorable effects of naringenin along with its more potency and efficacy, compared with other antioxidants, indicate that naringenin may be a promising therapeutic approach for the management of NAFLD and associated complications. However, due to the lack of clinical trials, future robust human randomized clinical trials that address the effects of naringenin on NAFLD and other liver-related diseases are crucial. Further careful human pharmacokinetic studies are also needed to establish dosage ranges, as well as addressing preliminary safety and tolerability of naringenin, before proceeding to larger-scale endpoint trials.

Citing Articles

Naringenin cationic lipid-modified nanoparticles mitigate MASLD progression by modulating lipid homeostasis and gut microbiota.

Dong L, Lou W, Xu C, Wang J J Nanobiotechnology. 2025; 23(1):168.

PMID: 40038718 PMC: 11881431. DOI: 10.1186/s12951-025-03228-x.


The Effect of Flavonoids and Topiramate on Glucose Carbon Metabolism in a HepG2 Steatosis Cell Culture Model: A Stable Isotope Study.

Ma L, Lu Q, Lim S, Han G, Boros L, Desai M Nutrients. 2025; 17(3).

PMID: 39940422 PMC: 11820484. DOI: 10.3390/nu17030564.


Drug Advances in NAFLD: Individual and Combination Treatment Strategies of Natural Products and Small-Synthetic-Molecule Drugs.

Wan X, Ma J, Bai H, Hu X, Ma Y, Zhao M Biomolecules. 2025; 15(1).

PMID: 39858534 PMC: 11764138. DOI: 10.3390/biom15010140.


The Effects of Novel Co-Amorphous Naringenin and Fisetin Compounds on a Diet-Induced Obesity Murine Model.

Vasquez-Reyes S, Bernal-Gamez M, Dominguez-Chavez J, Mondragon-Vasquez K, Sanchez-Tapia M, Ordaz G Nutrients. 2025; 16(24.

PMID: 39771046 PMC: 11678459. DOI: 10.3390/nu16244425.


Naringenin Nanoformulations for Neurodegenerative Diseases.

Sahoo L, Tripathy N, Dilnawaz F Curr Pharm Biotechnol. 2024; 25(16):2108-2124.

PMID: 38347794 DOI: 10.2174/0113892010281459240118091137.


References
1.
Stojsavljevic S, Gomercic Palcic M, Virovic Jukic L, Smircic Duvnjak L, Duvnjak M . Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol. 2015; 20(48):18070-91. PMC: 4277948. DOI: 10.3748/wjg.v20.i48.18070. View

2.
Zhao L, Zhang N, Yang D, Yang M, Guo X, He J . Protective Effects of Five Structurally Diverse Flavonoid Subgroups against Chronic Alcohol-Induced Hepatic Damage in a Mouse Model. Nutrients. 2018; 10(11). PMC: 6266428. DOI: 10.3390/nu10111754. View

3.
Harrison S, Day C . Benefits of lifestyle modification in NAFLD. Gut. 2007; 56(12):1760-9. PMC: 2095707. DOI: 10.1136/gut.2006.112094. View

4.
Abenavoli L, Milic N, Luzza F, Boccuto L, De Lorenzo A . Polyphenols Treatment in Patients with Nonalcoholic Fatty Liver Disease. J Transl Int Med. 2017; 5(3):144-147. PMC: 5688531. DOI: 10.1515/jtim-2017-0027. View

5.
Eslamparast T, Eghtesad S, Poustchi H, Hekmatdoost A . Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease. World J Hepatol. 2015; 7(2):204-12. PMC: 4342602. DOI: 10.4254/wjh.v7.i2.204. View